Fierce Biotech

Subscribe to Fierce Biotech feed
Updated: 1 hour 8 min ago

Illumina sets aside $453M to prep for potential EU fines over Grail acquisition

Fri, 08/12/2022 - 14:36
Illumina sets aside $453M to prep for potential EU fines over Grail acquisition chale Fri, 08/12/2022 - 17:36

Checkpoint calls it quits on cancer drug trial, citing enrollment problems stemming from war in Ukraine

Fri, 08/12/2022 - 09:25
Checkpoint calls it quits on cancer drug trial, citing enrollment problems stemming from war in Ukraine mbayer Fri, 08/12/2022 - 12:25

Abbott brings €440M and 1,000 jobs to Ireland to ramp up diabetes tech production

Fri, 08/12/2022 - 08:54
Abbott brings €440M and 1,000 jobs to Ireland to ramp up diabetes tech production apark Fri, 08/12/2022 - 11:54

FDA urges public to use multiple at-home COVID-19 tests to avoid false-negative results

Fri, 08/12/2022 - 08:23
FDA urges public to use multiple at-home COVID-19 tests to avoid false-negative results chale Fri, 08/12/2022 - 11:23

CPAP machine competitor ResMed nears $3.6B revenue in first year of Philips’ ventilator recall

Fri, 08/12/2022 - 07:24
CPAP machine competitor ResMed nears $3.6B revenue in first year of Philips’ ventilator recall apark Fri, 08/12/2022 - 10:24

Mount Sinai spins out vaccine Castle, preparing to lay siege to infectious diseases

Fri, 08/12/2022 - 06:59
Mount Sinai spins out vaccine Castle, preparing to lay siege to infectious diseases mbayer Fri, 08/12/2022 - 09:59

Oyster Point plows ahead with 50 layoffs to focus on approved eye drug

Fri, 08/12/2022 - 06:32
Oyster Point plows ahead with 50 layoffs to focus on approved eye drug jwaldron Fri, 08/12/2022 - 09:32

Walls close in on VistaGen's PALISADE anxiety trial program in wake of phase 3 failure

Fri, 08/12/2022 - 06:16
Walls close in on VistaGen's PALISADE anxiety trial program in wake of phase 3 failure aarmstrong Fri, 08/12/2022 - 09:16

Strike 3: Aptinyx's pain prospect flunks third midphase trial, sending stock to the basement

Fri, 08/12/2022 - 05:24
Strike 3: Aptinyx's pain prospect flunks third midphase trial, sending stock to the basement ntaylor Fri, 08/12/2022 - 08:24

Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing

Fri, 08/12/2022 - 04:57
Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing ntaylor Fri, 08/12/2022 - 07:57

Larimar's lead candidate still in limbo as company preps FDA response and maybe a new trial, too

Fri, 08/12/2022 - 03:13
Larimar's lead candidate still in limbo as company preps FDA response and maybe a new trial, too jwaldron Fri, 08/12/2022 - 06:13

Brain immune cells 'listen in' to neurons, offering new direction for neurological drug research

Thu, 08/11/2022 - 15:08
Brain immune cells 'listen in' to neurons, offering new direction for neurological drug research aliu Thu, 08/11/2022 - 18:08

Chutes & Ladders—J&J's Mammen abruptly vacates top R&D post

Thu, 08/11/2022 - 15:05
Chutes & Ladders—J&J's Mammen abruptly vacates top R&D post mbayer Thu, 08/11/2022 - 18:05

Abbott's concussion blood test helps predict death, disability after 6 months: study

Thu, 08/11/2022 - 11:09
Abbott's concussion blood test helps predict death, disability after 6 months: study chale Thu, 08/11/2022 - 14:09

SyncThink's brain-testing VR tech goes international with European approval

Thu, 08/11/2022 - 09:14
SyncThink's brain-testing VR tech goes international with European approval apark Thu, 08/11/2022 - 12:14

Cue Health plots next at-home tests while still raking in COVID profits for now

Thu, 08/11/2022 - 07:36
Cue Health plots next at-home tests while still raking in COVID profits for now apark Thu, 08/11/2022 - 10:36

Q2 2022 was weakest quarter for biotech IPOs in more than 5 years

Thu, 08/11/2022 - 07:17
Q2 2022 was weakest quarter for biotech IPOs in more than 5 years mbayer Thu, 08/11/2022 - 10:17

Band of biotechs cut pipeline prospects to focus cash on priority programs

Thu, 08/11/2022 - 05:47
Band of biotechs cut pipeline prospects to focus cash on priority programs ntaylor Thu, 08/11/2022 - 08:47

With no-go from FDA, Affimed looks elsewhere for its AML bispecific's first human study

Thu, 08/11/2022 - 05:25
With no-go from FDA, Affimed looks elsewhere for its AML bispecific's first human study aarmstrong Thu, 08/11/2022 - 08:25

Bolt, still flush with IPO cash, cans candidate over off-target toxicity, pauses other work to extend runway

Thu, 08/11/2022 - 03:40
Bolt, still flush with IPO cash, cans candidate over off-target toxicity, pauses other work to extend runway ntaylor Thu, 08/11/2022 - 06:40